Suppr超能文献

心房颤动合并左心室收缩功能障碍患者导管消融的五年随访结果

Five-year outcomes of catheter ablation in patients with atrial fibrillation and left ventricular systolic dysfunction.

作者信息

Bunch T Jared, May Heidi T, Bair Tami L, Jacobs Victoria, Crandall Brian G, Cutler Michael, Weiss J Peter, Mallender Charles, Osborn Jeffrey S, Anderson Jeffrey L, Day John D

机构信息

Intermountain Heart Institute, Intermountain Medical Center, Murray, Utah, USA.

出版信息

J Cardiovasc Electrophysiol. 2015 Apr;26(4):363-370. doi: 10.1111/jce.12602. Epub 2015 Feb 11.

Abstract

BACKGROUND

Catheter ablation of atrial fibrillation (AF) is an established therapy for symptomatic patients. The long-term efficacy and impact of catheter ablation among patients with severe systolic heart failure (SHF) requires additional study to understand if outcomes achieved at 1 year are maintained and mechanisms of AF recurrence.

METHODS

Three groups with SHF and 5 years of follow-up were matched 1:4:4 by age (±5 years) and sex: AF ablation patients receiving their first ablation (n = 267), AF patients that did not receive an ablation (n = 1,068), and SHF patient without AF (n = 1,068). SHF was based upon clinical diagnosis and an ejection fraction (EF) ≤35%. Patients were followed for 5-year primary outcomes of AF recurrence, heart failure, stroke, death, and cardiac function.

RESULTS

At 5 years, 60.7% of patients had clinical recurrence of AF. Diabetes and a prior heart attack were significant predictors of long-term risk of AF recurrence. Long-term mortality rates were 27%, 55%, 50%, in the AF ablation, AF, and no AF groups, respectively (P < 0.0001), with the lower rates attributed to lower cardiovascular mortality. At 5 years, there was no difference in EF, yet HF hospitalizations were lower following AF ablation compared to patients with AF and no ablation. Stroke rates at 5 years trended to be lower in the AF ablation group, but the difference was not statistically significant.

CONCLUSION

Recurrence rates of AF in patients with SHF after ablation are common at 5 years with an anticipated ongoing increase. Long-term AF-related comorbidities tended to be less in the AF ablation group.

摘要

背景

导管消融治疗心房颤动(AF)是一种针对有症状患者的既定疗法。对于严重收缩性心力衰竭(SHF)患者,导管消融的长期疗效和影响需要进一步研究,以了解1年时取得的疗效是否能维持以及房颤复发的机制。

方法

将三组患有SHF且随访5年的患者按年龄(±5岁)和性别以1:4:4进行匹配:接受首次消融的房颤消融患者(n = 267)、未接受消融的房颤患者(n = 1,068)以及无房颤的SHF患者(n = 1,068)。SHF基于临床诊断且射血分数(EF)≤35%。对患者进行5年的随访,观察房颤复发、心力衰竭、中风、死亡和心功能等主要结局。

结果

5年时,60.7%的患者出现房颤临床复发。糖尿病和既往心脏病发作是房颤复发长期风险的重要预测因素。房颤消融组、房颤组和无房颤组的长期死亡率分别为27%、55%、50%(P < 0.0001),较低的死亡率归因于较低的心血管死亡率。5年时,射血分数无差异,但与房颤患者和未消融患者相比,房颤消融后心力衰竭住院率较低。房颤消融组5年时的中风发生率有降低趋势,但差异无统计学意义。

结论

SHF患者消融后房颤复发率在5年时很常见,且预计会持续增加。房颤消融组与房颤相关的长期合并症往往较少。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验